Additionally, on July 15, 2014, the company announced the completion of the final formulation of its new Canna Liniment product line of topical analgesics. The products are made with cannabis oil, wintergreen essential oil and menthol and are formulated for the ailment of chronic pain and muscle soreness. The company indicated a total 89,525,000 common shares outstanding as of June 13, 2014, valuing the company at $71,620,000. Unfortunately, MediJane issued a notification of late filing in a form 12b-25 dated July 15, 2014. Since the company was not able to timely complete its financial statements to electronically file form 10-Q, there is very limited public information regarding the ongoing operations of the company. Going Public To Cash In On Marijuana Mania MediJane Holdings does not cultivate marijuana. They also do not engage in the research and development of their own independent cannabinoid products. They own no U.S. issued patents.